title: IL-12 gene therapy for cancer: in synergy with other immunotherapies.
abstract: In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.
authors: I
authors: I
authors: Melero
authors: G
authors: G
authors: Mazzolini
authors: I
authors: I
authors: Narvaiza
authors: C
authors: C
authors: Qian
authors: L
authors: L
authors: Chen
authors: J
authors: J
authors: Prieto
mesh_terms: D053330:4-1BB Ligand; D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology; D051940:B7-2 Antigen; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000276:immunology; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D019409:Interleukin-15 / Q000276:immunology; D020382:Interleukin-18 / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
chemical_list: D053330:4-1BB Ligand; D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497964:CD86 protein, human; C497965:Cd86 protein, mouse; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D019409:Interleukin-15; D020382:Interleukin-18; D007376:Interleukin-2; D008562:Membrane Glycoproteins; C505974:TNFSF9 protein, human; C505975:Tnfsf9 protein, mouse; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12